Objective-To determine the factors associated with the occurrence of Pneumocystis carinil pneumonia (PCP) in Wegener's granulomatosis (WG). Methods (PCP) is one of the most frequent and opportunistic, often resulting in death.3 It is therefore important to identify patients with WG who are at risk of PCP in order that they receive primary antipneumocystis prophylaxis. To determine the factors associated with the occurrence of PCP in WG, we compared retrospectively a group of 12 patients with both WG and PCP, with all patients suffering from WG, but without PCP, followed in the same units over the same period.
Results

PATIENT CHARACTERISTICS
PCPgroup-Some of the clinical and biological characteristics of the 12 patients of the PCP group have been described in a previous study.5 Briefly, the mean delay before onset of PCP was 128 (SD 127) days after the beginning of immunosuppressive therapy (median 90 days, range 50-510). PCP developed in the three months following the start of the treatment in most patients (eight of 12 patients) and was not chronologically related to the tapering of corticosteroid treatment.
Control group-Among the 51 patients suffering from WG without PCP followed in the same centres over the same period, 32 were included in the control group. Nine patients were not included for the following reasons: localised WG without systemic manifestations (three), HIV infection (one), and primary anti-PCP prophylaxis (five). Ten other patients were excluded because insufficient data were available or they were not followed regularly in the centres involved in the study. The mean period of observation of the control group was 19-5 (9 5) The mean cumulative dose of corticosteroids (by mouth, and pulses) was similar in the PCP group and control group at the end of the first month (2 6 (1 2) mg/kg/day v 2-38 (1-2) mg/ kg/day; p=O057), the second month (1 83 (0 7) mg/kg/day v 1 62 (0 6) mg/kg/day; p = 041), and the third month (15 (0-7) mg/ kg/day v 1 34 (0-5) mg/kg/day; p = 05). In contrast, the mean cumulative dose of cyclophosphamide was greater in the PCP group at the end of both the second and third months (fig 2) . There was a significant negative correlation between cyclophosphamide cumulative doses at months 1, 2, and 3, and the respective lymphocyte count at months 1, 2, and 3 (all r values between 0 50 and 0 54, p < 0 01). results of the multivariate analysis showed that lymphocyte count before and during treatment appears to be better than cyclophosphamide as a predictive factor for risk of PCP.
Primary anti-PCP prophylaxis is effective in AIDS patients.'3 The frequency and severity of PCP in WG justifies a similar prophylaxis, mainly with trimethoprim-sulphomethoxazole, as it has been suggested that this drug may also be useful in the treatment of WG.14 However, in view of the potential side effects associated with this drug, particularly cutaneous and haematological toxicity, our results suggest that primary prophylaxis is indicated most appropriately for patients whose lymphocyte count decreases to less than 600/mm3 during the first three months of treatment. Further studies are required to define these limits more clearly.
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